Abstract
Immunization of pregnant women against seasonal influenza remains limited in low- and lower-middle-income countries despite being recommended by the World Health Organization (WHO). The WHO/PATH Maternal Influenza Immunization Project was created to identify and address obstacles to delivering influenza vaccines to pregnant women in low resource setting. To gain a better understanding of potential demand from this target group, we developed a model simulating pregnant women populations eligible for vaccination during antenatal care (ANC) services in all low- and lower-middle-income countries. We assessed potential vaccine demand in the context of both seasonal and year-round vaccination strategies and identified the ways that immunization programs may be affected by availability gaps in supply linked to current vaccine production cycles and shelf life duration. Results of our analysis, which includes 54 eligible countries in 2015 for New Vaccine Support from Gavi, the Vaccine Alliance, suggest the demand for influenza vaccines could be 7.7 to 16.0 million doses in 2020, and 27.0 to 61.7 million doses by 2029. If current trends in production capacity and actual production of seasonal influenza vaccines were to continue, global vaccine supply would be sufficient to meet this additional demand—although a majority of countries would face implementation issues linked to timing of supply.
Highlights
The World Health Organization (WHO) recommends that countries expanding or initiating influenza vaccine programs prioritize pregnant women for vaccine receipt [1]
The base case scenario examines demand in countries that were eligible to apply for New Vaccine Support (NVS) from Gavi in 2015 and applies the values described above for the model parameters
We describe a model estimating the potential demand for seasonal influenza vaccines should maternal immunization programs be introduced in low- and lower-middleincome countries
Summary
The World Health Organization (WHO) recommends that countries expanding or initiating influenza vaccine programs prioritize pregnant women for vaccine receipt [1]. Despite the evidence of vaccine safety and efficacy [5,6,7,8], implementation of maternal influenza immunization programs has been limited in low- and lower-middleincome countries [9;10]. Forecasting demand for maternal influenza immunization in low- and lower-middle-income countries the decisions, policy or views of the World Health Organization. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.